Clinical Trial Update: A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection [Phase 2]

View source ↗

Summary

Phase 2 trial investigating P1101 plus TAF with or without UDCA in hepatitis D/HBV co-infected patients; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• P1101
• TAF (tenofovir alafenamide)
• UDCA (ursodeoxycholic acid)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Hepatitis D | Phase 2 | Status: UNKNOWN